1-4 of 4
Sylvain Ladoire
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P5-10-10: PELICAN-IPC 2015-016/Oncodistinct-003: a randomized phase II study of pembrolizumab in combination with neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer

Free
Alexandre de Nonneville, Florence Lerebours, Christophe Zemmour, Florence Dalenc, Christelle Levy, Thierry Petit, Marianne Leheurteur, Thomas Bachelot, Olivier Tredan, Sylvain Ladoire, Frédéric Viret, Leonor Lopez Almeida, Muge Kaya, Jean-Marie Boher, François Bertucci, Emmanuelle Charafe, Anthony Gonçalves
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P5-10-10.
https://doi.org/10.1158/1557-3265.SABCS24-P5-10-10
Published: 13 June 2025
View articletitled, Abstract P5-10-10: PELICAN-IPC 2015-016/Oncodistinct-003: a randomized phase II study of pembrolizumab in combination with neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer
Journal Articles

Abstract PS11-02: [18F]fluoroestradiol (FES) PET/CT to guide 2nd line treatment decision in patients with ER-positive HER2-negative advanced breast cancer (ABC) progressing on 1st line aromatase inhibitor and CDK4/6 inhibitor: early results of the ESTROTIMP trial

Free
Francois-Clement Bidard, Bidard, Romain-David Seban, Stephanie van de Ven, Sylvain Ladoire, Audrey Bellesoeur, Sandrine Parisse-Di Martino, Olivier Humbert, Thibaut Cassou-Mounat, Emmanuel Deshayes, Loic Djaileb, Khaldoun Kerrou, Eve Piekarski, Elise Deluche, Alexandre Cochet
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): PS11-02.
https://doi.org/10.1158/1557-3265.SABCS24-PS11-02
Published: 13 June 2025
View articletitled, Abstract PS11-02: [18F]fluoroestradiol (FES) PET/CT to guide 2nd line treatment decision in patients with ER-positive HER2-negative advanced breast cancer (ABC) progressing on 1st line aromatase inhibitor and CDK4/6 inhibitor: early results of the ESTROTIMP trial
Journal Articles

Associating Immunotherapy and Targeted Therapies: Facts and Hopes

Available to Purchase
Sylvain Ladoire, Cédric Rébé, François Ghiringhelli
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (7): 1183–1193.
https://doi.org/10.1158/1078-0432.CCR-22-1184
Published: 03 April 2023
View articletitled, Associating Immunotherapy and Targeted Therapies: Facts and Hopes
Open the PDF for Associating Immunotherapy and Targeted Therapies: Facts and Hopes in another window
Includes: Supplementary data
Journal Articles

Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells

Free
Sylvain Ladoire, Laurent Arnould, Lionel Apetoh, Bruno Coudert, Francois Martin, Bruno Chauffert, Pierre Fumoleau, François Ghiringhelli
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (8): 2413–2420.
https://doi.org/10.1158/1078-0432.CCR-07-4491
Published: 15 April 2008
View articletitled, Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells
Open the PDF for Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells in another window